Coroval

Quick links to important sections

Coroval

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coroval

Coroval is a prescription-only medicine that contains the active ingredient Amlodipine. It is fundamentally classified as a Calcium Channel Blocker (CCB), which is the basis for its therapeutic use in managing circulatory conditions. The drug is typically administered orally.

Property Description
Active ingredient Amlodipine (typically as Amlodipine besylate)
Form Tablet (also available as oral solution/suspension)
Pharmacological class Calcium Channel Blocker (CCB)
Common use Antihypertensive and Antianginal Agent
Origin Synthetic

What is the Drug Coroval and Its Core Classification?

Coroval contains Amlodipine, a synthetic small molecule that is a dihydropyridine derivative, distinguishing it within the broader class of Calcium Ion Antagonists. Amlodipine is often presented as the stable salt, Amlodipine besylate, which is essential for its long-acting profile and supports effective once-daily administration. Its classification as a CCB is consistently affirmed by major regulatory bodies, defining its function as a slow-channel blocker that selectively inhibits the flow of calcium ions into vascular smooth muscle cells.


Coroval's Composition, Form, and General Purpose

Coroval is a single-ingredient product most commonly supplied as a tablet, though an oral solution or oral suspension may also be available to suit diverse patient needs. The primary therapeutic purpose of Coroval is to function as both an Antihypertensive Agent and an Antianginal Agent.

Its general benefit is achieved through peripheral arterial vasodilation—the relaxation of arterial walls. This mechanism decreases overall peripheral vascular resistance, thereby reducing the mechanical workload on the heart and establishing its utility in managing chronic circulatory strain.

What side effects are possible with Coroval?

Official Adverse Reactions and Frequency

The possible side effects of Coroval are formally classified based on their documented frequency in clinical studies and post-marketing surveillance. The most prevalent reaction, classified as Very Common in regulatory documents, is peripheral edema (swelling, typically of the ankles or feet).

Adverse reactions listed as Common typically involve the Nervous System (e.g., headache, dizziness, somnolence) and the Cardiovascular System (e.g., flushing, palpitations, fatigue), along with gastrointestinal disturbances (nausea, abdominal pain).

Reactions categorized as Uncommon or Very Rare encompass a wider range of effects across various System-Organ Classes, including psychiatric disorders (insomnia, depression) and musculoskeletal pain.

Serious Safety Considerations

Official regulatory documents cite the potential for rare but serious adverse reactions. These include the development of worsening angina or acute myocardial infarction in susceptible patients, particularly following the initiation or increase of the dose. Very rare but clinically significant hepatic events, such as jaundice and marked elevations of liver enzymes, have also been documented in post-marketing reports.

Population-Specific and Dose-Related Safety Notes

The official labeling includes safety considerations for specific populations. Patients with severe hepatic impairment exhibit significantly prolonged drug clearance and therefore require cautious use and slow dose adjustment. Similarly, the clearance may be reduced in older adults. The incidence of some common effects, such as edema, is explicitly documented as dose-related. The medicine is contraindicated in individuals with a known hypersensitivity to Amlodipine or other dihydropyridine derivatives.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations of Coroval (Amlodipine) overdosage and the emergency actions required, based strictly on government regulatory documents.

Feature Official Regulatory Documentation Finding
Documented overdose presentations Marked and prolonged systemic hypotension due to excessive peripheral vasodilation, reflex tachycardia, bradycardia, and potential progression to shock. Non-cardiogenic pulmonary edema has also been reported.
Physiological systems affected (as stated in label) Primarily the Cardiovascular system and Respiratory system.
Population-specific overdose notes (if applicable) Impaired hepatic function or advanced age may prolong overdose effects due to reduced drug clearance.
Emergency-response statements (as written in official documents) The mandate is to seek immediate medical attention for overdosage. Active cardiovascular support must be instituted for clinically significant hypotension.
When immediate medical help is required (label-derived phrasing only) Urgent help is required because profound and sustained hypotension may lead to shock and potentially death.

Overdose Classifications

Classification Detail Official Regulatory Documentation Finding
Severity classification (as defined in official documents) Overdose can result in profound and sustained hypotension which may lead to shock and potentially death.
Overdose-context constraints (as defined in official documents) No specific antidote is known; management relies entirely on symptomatic and supportive measures.

Official Overdose Statements

  • Overdosage presents with profound and prolonged systemic hypotension and excessive peripheral vasodilation.
  • Management involves providing symptomatic and supportive treatment, including the use of pressor agents for persistent hypotension.
  • Official guidance supports the consideration of gastric lavage, activated charcoal, and intravenous calcium gluconate to manage the overdose.
  • Continuous cardiac and blood pressure monitoring in a hospital setting is essential due to the drug’s extended duration of action.

Connection to the Overall Overdose Profile

The official regulatory profile for Coroval overdose is centered on the critical risk of hemodynamic instability and severe hypotension. This risk mandates that patients seek immediate medical attention for the required institution of active cardiovascular support. Since no specific antidote is known, regulatory guidance focuses exclusively on extended monitoring and supportive interventions to manage the documented clinical manifestations.

Therapeutic Uses of Coroval

What Coroval Treats: Main Uses and Benefits

Coroval is commonly used to help with the long-term management of cardiovascular conditions, including systemic hypertension and various forms of angina pectoris. This medicine is commonly used to help lower and control elevated blood pressure readings. The primary benefit provided is the sustained control of these high readings, which contributes to maintaining a sense of stability when symptoms are more noticeable.

This medication is considered relevant for easing symptoms related to chronic stable angina, vasospastic angina, and provides supportive therapeutic benefits for patients with documented Coronary Artery Disease (CAD). It is commonly applied in scenarios where patients experience symptoms that interfere with daily functioning or symptoms that create noticeable physiological strain. The overall role is to assist with managing symptoms related to physical discomfort, which supports patients during difficult symptomatic periods.

Quick Fact: Supportive Management for Ischemic Chest Discomfort Coroval is considered relevant for easing symptoms that cluster into patterns requiring supportive management, specifically those involving recurring or episodic chest discomfort related to coronary ischemia.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Coroval?

Eligibility for Coroval (Amlodipine) is strictly defined by regulatory guidelines, focusing on absolute contraindications and specific population limitations.

Absolute Non-Eligibility (Contraindications)

Coroval must not be used by patients with:

  • Known hypersensitivity to Amlodipine or to any other dihydropyridine derivative (due to potential class allergy).
  • Severe hypotension (very low blood pressure) or patients in shock (including cardiogenic shock).
  • Conditions causing obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis).
  • Haemodynamically unstable heart failure following a recent acute myocardial infarction.

Age and Physiological Restrictions

Population Group Eligibility Status (Regulatory Wording)
Adults (18+ years) Eligible for hypertension and angina.
Children under 6 years Safety and efficacy are not established.
Pediatric (6–17 years) Eligible only for the treatment of hypertension.
Older Adults Eligible, but caution is advised during dosage increase.
Pregnancy/Lactation Not established as safe in pregnancy; contraindicated or not recommended during breastfeeding.

Patients with hepatic impairment (liver function problems) are eligible but require caution and often necessitate the lowest starting dose. Renal impairment does not typically require dosage adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation confirms specific interaction patterns for Coroval (Amlodipine), primarily involving pharmacokinetic modifications and additive effects.

Interaction Type Interacting Substance/Class Regulatory Outcome/Restriction
Metabolic (Pharmacokinetic) Strong and Moderate CYP3A4 Inhibitors (e.g., clarithromycin, diltiazem) Co-administration results in a documented increase in Coroval's systemic exposure (plasma concentrations).
Exposure Modification Simvastatin Coroval is documented to increase the systemic exposure of Simvastatin; the daily Simvastatin dose must not exceed 20 mg when co-administered.
Drug-Food/Substance Grapefruit or Grapefruit Juice Increased bioavailability of Coroval is possible; co-administration is officially not recommended in regulatory sources.

Co-administration with other antihypertensive agents may produce an additive blood pressure-lowering effect, a documented pharmacodynamic interaction. The regulatory profile notes that Coroval may cause variable increases in blood trough concentrations of co-administered immunosuppressants, such as Tacrolimus and Cyclosporine, requiring consideration. Additionally, patients with severe hepatic impairment exhibit a significantly prolonged plasma elimination half-life, resulting in increased systemic exposure to Coroval.

Mechanism of Action

Coroval (Amlodipine) is a highly selective Calcium Channel Blocker that acts to modulate key cardiovascular signaling pathways, primarily by regulating the forces acting on the cardiovascular system.

t Selective Blockade of Vascular Calcium Channels

This domain covers the drug's interaction with its core molecular target: the voltage-dependent L-type calcium channels on vascular smooth muscle cells. By inhibiting the influx of calcium ions, the drug directly suppresses the excitation-contraction coupling pathway, leading to arterial smooth muscle relaxation.

◣️ Modulation of Systemic Vascular Resistance

The resulting widespread arterial relaxation initiates a systemic cascade by reducing the Systemic Vascular Resistance (SVR), or afterload. This action engages mechanisms that regulate the flow dynamics in the peripheral circulation, resulting in a reduction in the mechanical load imposed on the heart muscle.

️ Direct Regulation of Coronary Flow

The mechanism extends to the coronary arteries, resulting in the direct relaxation of the coronary vessels. This targeted pathway adjustment modifies the effect of excessive vascular tone by opposing calcium-dependent contraction, thereby modulating oxygen delivery to the myocardium.

Dosage and Administration Information

Coroval is administered orally and is provided primarily as a tablet in strengths of 2.5 mg, 5 mg, and 10 mg. The medicine is taken once daily to maintain consistent systemic concentrations, which reflects its long duration of action.

The standardized adult regimen for both systemic hypertension and chronic stable angina typically begins with a starting dose of 5 mg once per day. The dosage can be adjusted, but the maximum daily dose is limited to 10 mg. Dose changes must be spaced by at least 7 to 14 days to allow the full response to the current dose to be accurately assessed before any increase.

Coroval may be taken with or without food, allowing for flexibility regarding the time of day it is administered. For certain populations, the initial regimen must be modified: older adults and individuals with hepatic impairment are typically started on the lower dose of 2.5 mg once daily, and the dosage is titrated slowly. The standard regimen does not typically require adjustment for patients with renal impairment. Coroval is used as part of a long-term management plan and is not intended for short-term or cyclical use.

Recent Clinical Evidence

Apixaban is an oral anticoagulant medication that holds approved indications for the prevention and treatment of thromboembolism. It is classified as a direct-acting oral anticoagulant (DOAC).

Apixaban holds approved indications for several major cardiovascular and hematological conditions. These include the prevention of stroke and systemic embolism in individuals with nonvalvular atrial fibrillation (A-fib), the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE. It is also indicated for DVT prophylaxis following hip or knee replacement surgery.

Findings from Key Clinical Trials

Stroke Prevention in A-fib: Clinical trial data comparing apixaban to older anticoagulants indicate that the medication was associated with a reduced risk of stroke or systemic embolism. Furthermore, the rate of major bleeding was comparable to, or in some instances lower than, that observed with warfarin in certain patient populations.

Venous Thromboembolism (VTE) Treatment: Research findings support the use of apixaban for the acute treatment and extended prevention of recurrent VTE (DVT and PE). Studies demonstrate that apixaban was noninferior to conventional therapy (heparin/warfarin) in preventing recurrent VTE or VTE-related death, while being associated with significantly less major bleeding.

Investigational Uses: Ongoing research is assessing the findings related to its role in other conditions. This includes evaluating the use of apixaban as part of combination therapy after coronary stenting (PCI) in patients with A-fib, and for the treatment of cerebral venous thrombosis (CVT). These potential uses remain under active investigation and are not within the currently approved indications.

Frequently Asked Questions (FAQ)

Common questions about Coroval (FAQ)


Q: How long does it typically take to feel an effect from Coroval?

After taking an oral dose, the concentration of Coroval in the bloodstream generally reaches its peak within 6 to 12 hours. However, official guidance notes that dose changes must be spaced by at least 7 to 14 days to allow the full response to be assessed.


Q: Can people with kidney problems use Coroval?

Regulatory information indicates that Coroval's processing in the body is generally not significantly affected by kidney impairment. As a result, the standard starting dose typically does not need to be adjusted for patients with kidney problems.


Q: Can I take Coroval if I am pregnant or planning to be?

There is limited human data regarding the use of Coroval during pregnancy. Official guidance often states that its use is considered only when the prescriber determines the condition's risk to the mother and fetus outweighs the unknown risks of the medicine. Coroval is typically not recommended during breastfeeding.


Q: Can Coroval affect my ability to drive?

Certain common side effects documented in official labeling, such as dizziness, headache, and sleepiness (somnolence), could potentially impair alertness. Official guidance recommends caution, particularly when starting treatment or following a dose increase, due to these potential effects on alertness.


Q: Does Coroval affect blood pressure?

Yes, Coroval is officially classified as an antihypertensive agent, meaning its primary purpose is to lower blood pressure. It achieves this by working as a calcium channel blocker to relax and widen the blood vessels, reducing the resistance to blood flow.


Q: Are there any specific laboratory tests required while taking Coroval?

While routine laboratory monitoring tests are not universally mandated by official documents, monitoring of blood levels is required when Coroval is co-administered with certain immune-suppressing drugs, such as Tacrolimus or Cyclosporine.


Q: Is Coroval a medication that I have to take long-term?

Coroval is generally prescribed as part of a long-term management plan for chronic conditions like hypertension and angina. If the medicine is discontinued, the effects on blood pressure are not sustained, and blood pressure levels may return toward baseline.


Q: Is Coroval a type of antibiotic, painkiller, or something else?

Coroval contains Amlodipine, which is officially classified as a Calcium Channel Blocker (CCB). It is not an antibiotic, which treats bacterial infections, nor is it a painkiller used for general pain relief.


Q: Is it true that Coroval can make you feel sleepy?

Yes, official regulatory documents list sleepiness, known medically as somnolence, as a Common adverse reaction associated with Coroval.


Q: Is there a different name for Coroval, like a generic version?

The active ingredient in Coroval is Amlodipine. This is the generic name for the drug, and it is available to patients under this generic name as well as various brand names worldwide.


Q: What happens if I miss taking Coroval at the usual time?

Official patient information advises taking the missed dose as soon as it is remembered on that day. If an entire day has already passed, the missed dose should be skipped entirely, and the next scheduled dose should be taken at the usual time. Never take two doses at once to compensate for a missed dose.


Q: Is there any research that looks at the long-term safety of Coroval?

Since Coroval is used for chronic management, its regulatory approval is supported by extensive clinical trial data that includes long-term follow-up. Safety monitoring continues through post-marketing surveillance reports submitted to regulatory agencies.


Q: How does Coroval compare to other medicines for the same condition?

Coroval is chemically categorized as a dihydropyridine Calcium Channel Blocker (CCB). The clinical profile of the medicine is supported by studies that have examined its effects when used alone or in combination with other classes of blood pressure medications.


Q: Do children ever get prescribed Coroval?

Yes, official documentation confirms that Coroval is approved for use in the pediatric population. Its use is specifically authorized for children and adolescents aged 6 to 17 years for the treatment of hypertension (high blood pressure) only.


Q: Does Coroval have any known effects on mood or anxiety?

Official documents list specific psychiatric disorders as Uncommon adverse reactions associated with Coroval. These documented effects include insomnia (trouble sleeping) and depression.


Q: Can Coroval cause a change in weight?

Weight gain is listed as an Uncommon adverse reaction in the official documentation. This is sometimes seen alongside the Very Common side effect of peripheral edema, which is the documented swelling of the ankles or feet.


Q: How should Coroval be stored at home?

Official regulatory guidance specifies that Coroval should be stored at a controlled room temperature, typically around 20 C to 25 C (68 F to 77 F). It should be kept in its original, tightly sealed container and protected from both moisture and excessive heat.


Q: Is Coroval known to cause allergic reactions?

Yes, regulatory documents list a known hypersensitivity, or allergy, to Amlodipine or other related dihydropyridine derivatives as an absolute contraindication, meaning the drug should not be used in such cases.


Q: Is there an official patient leaflet that explains Coroval?

Yes, regulatory agencies mandate that manufacturers provide a Patient Medication Information leaflet or a Patient Package Insert. This document summarizes the drug's essential information, including its use, safety, and administration, in language intended for the general public.


Q: Are the side effects from Coroval temporary or do they last a long time?

Many common side effects, such as headache or flushing, are often reported as temporary and may lessen as the body adjusts to the medicine. However, official information notes that some effects, like peripheral edema (swelling), can be dose-related and may persist until the dosage is adjusted.


Q: Why do doctors prescribe Coroval instead of other treatments?

Official documents characterize Coroval by its specific mechanism as a calcium channel blocker, its demonstrated clinical effects, and its long duration of action supporting once-daily administration. These documented characteristics support its use in managing chronic circulatory conditions.


Q: Is Coroval a new medication, or has it been around for a while?

Coroval contains Amlodipine, an active ingredient that has been approved and widely used globally for the management of chronic circulatory conditions for several decades.


Q: What if I start feeling worse after I begin taking Coroval?

Official patient instructions recommend contacting a healthcare professional immediately if new or worsening symptoms occur after starting Coroval. This is particularly important for signs of serious adverse reactions, such as worsening angina (chest pain).


Q: Does the time of day I take Coroval matter?

While the medicine can be taken with or without food for flexibility, regulatory guidance recommends taking it once daily at about the same time each day. This practice helps to ensure consistent drug levels are maintained in the body, which is important for long-term management.


Q: What types of food should I try to avoid when on Coroval?

Regulatory documentation specifically advises against the co-administration of Coroval with grapefruit or grapefruit juice. This is because co-administration with these substances is documented to increase the drug's systemic exposure, which is why official sources advise against it.


Q: Is Coroval considered a high-risk medication?

Official documents do not categorize the drug using simple 'high-risk' labels. Its safe use is assured by detailed warnings, precautions, and contraindications that are clearly specified in the official prescribing information and require medical supervision.


Q: Can taking Coroval affect fertility?

Non-clinical, laboratory studies conducted in male rats have shown potential effects on fertility. However, official regulatory documentation contains limited information regarding a direct effect on human fertility.


Q: If I have a mild side effect, should I continue taking Coroval?

Official patient instructions recommend discussing mild or bothersome side effects with a healthcare professional, who can determine the appropriate course of action. This is the recommended procedure for managing side effects.


Q: Can Coroval be crushed or chewed if I have trouble swallowing pills?

For patients who have difficulty swallowing tablets, specific compounding guidelines or patient leaflets should be consulted. Consultation should be made for the specific product formulation to confirm if this practice is appropriate and safe.


Q: Does Coroval contain gluten, lactose, or other common allergens?

Official drug labels are required to list all inactive ingredients, or excipients, including substances like lactose or other potential allergens. Patients with known sensitivities should review the full list of ingredients with their prescribing professional.

How should Coroval be stored and disposed of?

How to Store and Dispose of Coroval (Amlodipine)

Coroval must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted. The medicine must be kept in its original container, which should be tightly closed, and protected from moisture and excessive heat. For safety, Coroval must be stored out of the reach and sight of children.

Disposal Requirements

Unused or expired Coroval should not be flushed down the toilet or disposed of in household trash. Patients should seek a local drug take-back program. If no program is available, the product must be mixed with an undesirable substance, placed in a sealed container, and then discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coroval found in:

A-Z Index: